While registration is required for all attendees, the ASCO20 Virtual Scientific Program meeting fees will be discounted for non-members and waived completely for ASCO members. Registration will open in late April, and attendees of the ASCO20 Virtual Scientific Program will also receive access to the...
Advances in The Management of Non-Small Cell Lung Cancer (NSCLC): A new practice changing data from ASCO 2020 Annual Meeting - ScienceDirectMohammed Sqalli Houssaini Conceptualization; Methodology; Writing – Review & Editing a bMeriem Damou Ressources; Software a b...
近日,2020年美国临床肿瘤学会年会(2020 ASCO Annual Meeting)组委会正式通知:由东部战区总医院秦叔逵教授和四川大学华西医院毕锋教授共同牵头、全国37家肿瘤中心联合开展的“多纳非尼对比索拉非尼一线治疗晚期肝细胞癌(HCC)的开放标签、随机对照、...
Elahere是首个在铂类耐药卵巢癌患者上显示带来总生存期改善的疗法。 图注:www.biospace.com/article/releases/immunogen-announces-results-from-the-phase-3-mirasol-trial-selected-as-late-breaking-presentation-for-asco-2023-annual-meeting/ 卵巢癌患者对含铂疗法产生耐...
oct 12, 2025 online & in-person | chicago, il subscribe for updates arrow_back_ios arrow_forward_ios most viewed text_snippet videos & slides 2023 asco annual meeting phase ii trial of neoadjuvant osimertinib for surgically resectable egfr -mutated non-small cell lung cancer. first author: ...
3.2024 ASCO Annual Meeting – BeiGene Presentations 4.Innovent Announces the Preclinical Results of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) were Published in Nature 本文内容来源:BiG生物创新社 作者:小麦 注:版权归原作者所有,仅供读者学习、研究或者欣赏,不得用于商业用途 ...
Explore the latest advancements in lung cancer treatment discussed at the Annual Meeting of the American Society of Clinical Oncology (ASCO24). This summary highlights key studies on NSCLC and SCLC, both early and metastatic.
At this ASCO annual meeting, many emerging biotechnology companies also released their latest clinical data on some new targets. #1 Junshi BTLA B and T lymphocyte attenuator (BTLA), as an immune checkpoint molecule, has similar structure and intracellular signaling mechanism with other immune ...
SUZHOU, China, May 15, 2020 /PRNewswire/ -- Innovent Announces Key Results from a Number of Clinical Studies to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting
”MacroGenics总裁兼CEO Scott Koenig博士说道。后台回复ADC，即可下载MGC018 ASCO电话会议36页完整PDF。参考资料：1#MacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting（来源：MacroGenics）